Abstract
SARS-CoV-2 lineage B.1.1.7, a variant first detected in the United Kingdom in September 20201, has spread to multiple countries worldwide. Several studies have established that B.1.1.7 is more transmissible than preexisting variants, but have not identified whether it leads to any change in disease severity2. We analyse a dataset linking 2,245,263 positive SARS-CoV-2 community tests and 17,452 COVID-19 deaths in England from 1 September 2020 to 14 February 2021. For 1,146,534 (51%) of these tests, the presence or absence of B.1.1.7 can be identified because of mutations in this lineage preventing PCR amplification of the spike gene target (S gene target failure, SGTF1). Based on 4,945 deaths with known SGTF status, we estimate that the hazard of death associated with SGTF is 55% (95% CI 39–72%) higher after adjustment for age, sex, ethnicity, deprivation, care home residence, local authority of residence and test date. This corresponds to the absolute risk of death for a 55–69-year-old male increasing from 0.6% to 0.9% (95% CI 0.8–1.0%) within 28 days after a positive test in the community. Correcting for misclassification of SGTF and missingness in SGTF status, we estimate a 61% (42–82%) higher hazard of death associated with B.1.1.7. Our analysis suggests that B.1.1.7 is not only more transmissible than preexisting SARS-CoV-2 variants, but may also cause more severe illness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from UK Research and Innovation, the National Institutes of Health Research (NIHR) Health Protection Research Unit in Immunisation [NIHR200929], and the UK Medical Research Council [MC_PC_19065] (NGD); Global Challenges Research Fund project 'RECAP' managed through Research Councils UK and the Economic and Social Research Council [ES/P010873/1] (CIJ); European Commission project 'EpiPose' [101003688] and the NIHR [NIHR200908] (WJE); the National Institutes of Health / National Institute of Allergy and Infectious Diseases [R01AI148127] (NPJ); a Royal Society-Wellcome Trust Sir Henry Dale Fellowship [218554/Z/19/Z] (KDO); and a UKRI Future Leaders Fellowship [MR/S017968/1] (RHK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by the Observational / Interventions Research Ethics Committee at the London School of Hygiene and Tropical Medicine (reference number 24020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵§ A list of authors and their affiliations appears at the end of the paper.
Updated version.
Data Availability
All analysis code is publicly available. An anonymised data set allowing replication of the analysis is publicly available.
